REFERENCES
- Kranz G. Failure is not an option. Simon & Shuster, New York 2000; 12
- Wiesel E. Without conscious. N. Engl J. Med. 2005; 352: 1511–1513, [CSA]
- Faden R. R., Lederer S. E., Moreno J. D. US medical researchers, the Nuremberg doctors trial, and the Nuremberg code A review of findings of the Advisory Committee on Human Radiation Experiments. JAMA 1996; 276: 1667–1671, [CSA], [CROSSREF]
- Kaufman J. L., Pelligra R., Reingold A. L., Sackett D. L., Shapiro H. T., Mestin E. M., Woodward B. Protection for human subjects in medical research. JAMA 2000; 283: 2387–2390, [CSA], [CROSSREF]
- Shalala D. Protecting human subjects—what must be done. N. Eng. J. Med. 2000; 343: 808–810, [CSA], [CROSSREF]
- Angell M. Investigators responsibilities for human subjects in developing countries. N. Engl. J. Med. 2000; 342: 967–969, [CSA], [CROSSREF]
- Moreno J., Caplan A. L., Wolpe P. R. Updating protections for human subjects involved in research. JAMA 1998; 280: 1951–1958, [CSA], [CROSSREF]
- Stamatis D. H. Failure mode effect analysis: FMEA from theory to execution. American Society for Quality, Quality Press, Milwaukee, WI 2003
- McDermott R. E., Mikulak R. J., Beauregard M. R. The basics of FMEA. Productivity, Inc., Portland, OR 1996
- Roberts R. G., Jr, Goulart B. H., Squitieri L., Stallings S. C., et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292: 2130–2140, [CSA], [CROSSREF]
- Shah S., Whittle A., Wilfond B., Gensler G., Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research?. JAMA 2004; 291: 476–482, [CSA], [CROSSREF]
- Christian M. C., Goldberg J. L., Killen J., Abrams J. S., et al. A central institutional review board for multi-institutional trials. N. Engl. J. Med. 2002; 346: 1405–1408, [CSA], [CROSSREF]